We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $824M
1-Year Est. Return 78.19%
This Fund
S&P 500
This Quarter Est. Return
+8.32%
1 Year Est. Return
+78.19%
3 Year Est. Return
+156.18%
5 Year Est. Return
+168.38%
10 Year Est. Return
+388.18%
AUM
$727M
AUM Growth
-$8.17M
Cap. Flow
-$54.1M
Cap. Flow %
-7.43%
Top 10 Hldgs %
34.15%
Holding
170
New
10
Increased
34
Reduced
80
Closed
8

Top Sells

Rank Stock Value
1
VZ icon
Verizon
VZ
+$18.1M
2
T icon
AT&T
T
+$17M
3
AQN icon
Algonquin Power & Utilities
AQN
+$9.57M
4
FLS icon
Flowserve
FLS
+$6.46M
5
SYNA icon
Synaptics
SYNA
+$3.2M

Sector Composition

Rank Sector Weight
1 Technology 25.82%
2 Healthcare 23.86%
3 Utilities 17.96%
4 Industrials 17.19%
5 Communication Services 4.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PFE icon
1
Pfizer
PFE
$159B
$37.5M 5.16%
635,167
-8,283
-1% -$410K
EMR icon
2
Emerson Electric
EMR
$86.6B
$35.3M 4.85%
379,362
-6,405
-2% -$603K
OGE icon
3
OGE Energy
OGE
$9.45B
$30.8M 4.24%
803,564
+20,320
+3% +$712K
CSCO icon
4
Cisco
CSCO
$433B
$24.7M 3.4%
390,344
-3,673
-0.9% -$210K
BMY icon
5
Bristol-Myers Squibb
BMY
$136B
$24.3M 3.34%
389,544
-503
-0.1% -$29.5K
GLW icon
6
Corning
GLW
$128B
$24.1M 3.32%
647,406
+11,586
+2% +$434K
INTC icon
7
Intel
INTC
$473B
$19.1M 2.62%
370,402
+216
+0.1% +$11K
IBM icon
8
IBM
IBM
$222B
$18.8M 2.58%
140,540
-16,695
-11% -$2.09M
BCE icon
9
BCE
BCE
$21.9B
$17M 2.34%
327,106
-1,933
-0.6% -$98.8K
GSK icon
10
GSK
GSK
$102B
$16.7M 2.3%
302,766
-15,360
-5% -$799K
MDU icon
11
MDU Resources
MDU
$4.16B
$16.2M 2.23%
1,380,498
-7,626
-0.5% -$86K
NVS icon
12
Novartis
NVS
$292B
$15.6M 2.14%
178,239
+3,285
+2% +$273K
XOM icon
13
ExxonMobil
XOM
$644B
$14.2M 1.95%
231,521
-3,262
-1% -$204K
MMM icon
14
3M
MMM
$89.9B
$14M 1.92%
94,110
+6,529
+7% +$973K
LGTY
15
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
$13.2M 1.82%
505,641
-14,732
-3% -$392K
XRAY icon
16
Dentsply Sirona
XRAY
$2.22B
$13.1M 1.8%
234,733
+18,200
+8% +$1M
HE icon
17
Hawaiian Electric Industries
HE
$1.97B
$13M 1.79%
313,682
-1,600
-0.5% -$64.9K
MSFT icon
18
Microsoft
MSFT
$3.81T
$12.6M 1.74%
37,597
-468
-1% -$152K
TEL icon
19
TE Connectivity
TEL
$58.7B
$12.1M 1.66%
74,992
-742
-1% -$115K
TMO icon
20
Thermo Fisher Scientific
TMO
$230B
$11.8M 1.62%
17,666
-125
-0.7% -$78K
D icon
21
Dominion Energy
D
$57.7B
$11.6M 1.6%
148,282
-1,304
-0.9% -$98.1K
BKH icon
22
Black Hills Corp
BKH
$5.55B
$11.4M 1.57%
161,333
-550
-0.3% -$36.5K
ELAN icon
23
Elanco Animal Health
ELAN
$12B
$11M 1.51%
386,275
-19,990
-5% -$622K
POR icon
24
Portland General Electric
POR
$5.83B
$10.6M 1.45%
199,609
-720
-0.4% -$35.9K
MRK icon
25
Merck
MRK
$366B
$10.3M 1.42%
134,783
+7,260
+6% +$578K

Similar funds

John G. Ullman & Associates's Q4 2021 Portfolio in Review

As of Q4 2021, John G. Ullman & Associates held 170 positions worth $727M, down 1.1% from $735M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

John G. Ullman & Associates withdrew a net $54.1M in Q4 2021, closing 8 positions and reducing 80 holdings. Its most notable exit was Synaptics, an estimated $3.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Utilities.

Against the trend, John G. Ullman & Associates opened a new position in Vontier worth $1.63M.

  • John G. Ullman & Associates's largest Q4 2021 buy was Vontier: 53,095 shares worth $1.63M.
  • John G. Ullman & Associates added most to Fiserv Inc in Q4 2021, an estimated $3.37M increase.
  • John G. Ullman & Associates's biggest Q4 2021 reduction was Verizon, cutting an estimated $18.1M.
  • John G. Ullman & Associates fully exited Synaptics in Q4 2021, selling an estimated $3.2M.
  • John G. Ullman & Associates's ten largest holdings make up 34% of its $727M portfolio in Q4 2021.
  • John G. Ullman & Associates opened 10 new positions and closed 8 in Q4 2021.
  • John G. Ullman & Associates's portfolio value fell 1.1% quarter-over-quarter to $727M.

Based on John G. Ullman & Associates's 13F filing for Q4 2021, filed 26 Jan 2022.